|Starpharma Holdings Limited|
Baker IDI Building
75 Commercial Road
Australia - Map
Phone: 61 3 8532 2700
Fax: 61 3 9510 5955
Starpharma Holdings Limited researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia. The company focuses on the development of VivaGel, a microbicidal agent in Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for prevention of sexual transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel in Phase I clinical trial for breast, prostate, lung, and ovarian tumor; and agrochemicals. Starpharma Holdings Limited was founded in 1996 and is headquartered in Melbourne, Australia.
|Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA,
Chief Exec. Officer and Exec. Director
|Mr. Nigel J. Baade B.Com, CPA, Grad. Dip. Arts,
Chief Financial Officer and Company Sec.
|Dr. Jeremy R. Paull BSc (Hons), Ph.D.,
VP of Devel. & Regulatory Affairs
|Dr. C. Paul Barrett B.Sc. (Hons), Ph.D.,
VP of Bus. Devel.
|Dr. David J. Owen BSc(Hons) Ph.D.,
VP of Research
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|